Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $5.67.

Separately, HC Wainwright reduced their target price on shares of Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 1st.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $1.09 on Friday. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $4.09. The company has a 50-day simple moving average of $1.33 and a 200 day simple moving average of $1.05. The company has a market capitalization of $125.42 million, a PE ratio of -0.89 and a beta of 0.03.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $33.75 million for the quarter, compared to analysts’ expectations of $33.50 million. During the same period last year, the firm earned ($0.43) EPS. As a group, analysts forecast that Karyopharm Therapeutics will post -1.19 EPS for the current fiscal year.

Insider Activity at Karyopharm Therapeutics

In related news, CEO Richard A. Paulson sold 80,470 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $94,149.90. Following the completion of the transaction, the chief executive officer now owns 1,183,783 shares of the company’s stock, valued at $1,385,026.11. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Richard A. Paulson sold 80,470 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $94,149.90. Following the completion of the sale, the chief executive officer now directly owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Michael Mason sold 27,687 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $32,393.79. Following the completion of the sale, the chief financial officer now owns 404,918 shares of the company’s stock, valued at $473,754.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 171,331 shares of company stock valued at $206,118. Corporate insiders own 3.32% of the company’s stock.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC purchased a new position in Karyopharm Therapeutics during the 4th quarter valued at $33,000. GSA Capital Partners LLP purchased a new position in Karyopharm Therapeutics during the 3rd quarter valued at $762,000. Barclays PLC grew its position in shares of Karyopharm Therapeutics by 4.2% in the 3rd quarter. Barclays PLC now owns 1,152,298 shares of the company’s stock worth $1,544,000 after buying an additional 45,937 shares during the period. Exchange Traded Concepts LLC grew its position in shares of Karyopharm Therapeutics by 30.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 86,484 shares of the company’s stock worth $116,000 after buying an additional 20,062 shares during the period. Finally, SG Americas Securities LLC boosted its stake in Karyopharm Therapeutics by 295.0% in the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock worth $64,000 after purchasing an additional 54,839 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).